Nephrol Dial Transplant (2001) 16: 141-146
© 2001 European Renal Association-European Dialysis and Transplant Association
Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients
Medizinische Klinik IV, University of Erlangen-Nürnberg, Erlangen, Germany
Background. Hyperlipidaemia is an important risk factor for cardiovascular disease in renal transplant recipients. The aim of this study was to test the efficacy and possible drug–drug interactions of the new HMG-CoA reductase inhibitors (statins) atorvastatin and cerivastatin in cyclosporin A (CsA)-treated renal transplant patients.
Subjects and methods. Thirty patients with stable graft function and LDL cholesterol of 130 mg/dl were randomly assigned to active treatment groups (10 mg atorvastatin or 0.2 mg cerivastatin), or a control group. CsA blood trough levels were controlled on a weekly basis and adapted if they changed more than 25% from baseline values (100–150 ng/ml). Lipid levels and routine laboratory parameters before and after a treatment period of 3 months were compared.
Results. In the group treated with cerivastatin no significant changes in CsA blood trough levels occurred (CsA 116±21 ng/ml vs 110±20 ng/ml). In contrast, in the group treated with atorvastatin, four of 10 patients had a rise in CsA blood trough levels of more than 25% within 7–14 days of starting therapy. In the remaining patients no significant changes in CsA drug levels occurred. After therapy with atorvastatin or cerivastatin, total cholesterol, LDL cholesterol, and triglycerides were significantly lower compared with baseline conditions. No changes of CsA or lipoprotein levels were present in the control group.
Conclusion. In our study population both statins were very effective in lowering elevated LDL cholesterol levels. Cerivastatin did not influence CsA blood trough levels, whereas atorvastatin increased CsA levels in four of 10 patients. Further research in a larger study is necessary in order to confirm these results and to investigate the possible reasons for this drug interaction.
Keywords: atorvastatin; cerivastatin; cyclosporin A; cytochrome P450; hyperlipidaemia; renal transplantation
Correspondence and offprint requests to: Ingeborg A. Hauser MD, Medizinische Klinik IV, Funktionsbereich Nephrologie, Universitätsklinik Frankfurt/Main, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.
* Current address: Department of Nephrology, JWG-University of Frankfurt/Main D-60590 Frankfurt, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Kokudai, N. Inui, K. Takeuchi, T. Sakaeda, Y. Kagawa, and H. Watanabe Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers J. Clin. Pharmacol., May 1, 2009; 49(5): 568 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E C Jury and M R Ehrenstein Statins: immunomodulators for autoimmune rheumatic disease? Lupus, March 1, 2005; 14(3): 192 - 196. [Abstract] [PDF]
|
|
|
|
 |
|
 K. L. Lentine and D. C. Brennan Statin use after renal transplantation: a systematic quality review of trial-based evidence Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2378 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J Taylor, P. A Kubler, S. V Lynch, J. Allen, M. Butler, and P. I Pillans Effect of Atorvastatin on Cyclosporine Pharmacokinetics in Liver Transplant Recipients Ann. Pharmacother., February 1, 2004; 38(2): 205 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Johnson, A. T. Iacono, A. Zeevi, K. R. McCurry, and S. R. Duncan Statin Use Is Associated with Improved Function and Survival of Lung Allografts Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1271 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Elisaf and D. P. Mikhailidis Statins and Renal Function Angiology, September 1, 2002; 53(5): 493 - 502. [Abstract] [PDF]
|
|